SNORA13

Across TCGA pan-cancer cohorts, SNORA13 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of SNORA13’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where SNORA13 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SNORA13 is over-expressed in tumor.

LIHC, CHOL, and COAD are the cancer types where SNORA13 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SNORA13 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	II,III,IV	+0.459	<.001	7	view →
CHOL	Male	All	+1.796	<.001	5	view →
COAD	All	All	+0.765	<.001	5	view →
KIRC	All	All	+0.336	<.001	5	view →
BLCA	Male	III,IV	+1.481	.019	4	view →
READ	All	All	+1.102	<.001	3	view →
ESCA	Male	All	+1.034	.015	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

SNORA13–LIHC

Open the LIHC breakdown →